Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of PF-07321332/ritonavir in renal impairment
NCT04909853Phase 1Completed
- Sponsor
- Pfizer
- Start
- Jun 2021
- Primary completion
- Oct 2021
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Nirmatrelvir in coronavirus disease 2019 (COVID-19), sponsored by Pfizer. Primary endpoints: Maximum Observed Plasma Concentration at 48 hours, Area Under the Plasma Concentration-time Profile to Infinite Time at 48 hours and 2 more. Started Jun 2021; status: completed.
02
Drugs
Nirmatrelvir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04909853.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04909853.